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It is recently shown that beneficial environmental microbes stimulate integrated immune
and neuroendocrine factors throughout the body, consequently modulating regulatory
T-lymphocyte phenotypes, maintaining systemic immune balance, and determining the
fate of preneoplastic lesions toward regression while sustaining whole body good health.
Stimulated by a gut microbiota-centric systemic homeostasis hypothesis, we set out to
explore the influence of the gut microbiome to explain the paradoxical roles of regulatory
T-lymphocytes in cancer development and growth. This paradigm shift places cancer pre-
vention and treatment into a new broader context of holobiont engineering to cultivate a
tumor-suppressive macroenvironment.
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INTRODUCTION
The neoplastic process is characterized by overwhelming com-
plexity. Cancer is comprised of a genetically unstable population
of cells that proliferate at an extraordinarily high rate. Millions of
cancer deaths each year make it obvious that the battle against can-
cer is asymmetric, with humankind often being the weaker element
(1). To date, cancer research efforts directly confront malignancy
by targeting properties of individual cancer cells. In 2000, Hana-
han and Weinberg described that most of the research on origins
and treatment of cancer had just contributed toward “adding fur-
ther layers of complexity to a scientific literature that is already
complex almost beyond measure” (2).
In the same landmark paper, however, the authors were opti-
mistic enough to predict groundbreaking upcoming advances in
the conceptual rather than the technical level (2). They were proven
right. One such advancement was the increased awareness for the
importance of the tumor microenvironment in the etiopathogen-
esis of neoplasia (3, 4). We now know that initially transformed
cells are much less autonomous in their growth than previously
thought (5, 6). Among the microenvironment elements, immune
cells and factors have emerged as fundamental players (4–6).
Accumulating evidence suggests that tumor-associated inflam-
matory cell accumulation, whether overt or smoldering, could
be viewed as a tumor-promoting event (7–9). These inflamma-
tory responses enhance mutagenesis by oxidative DNA damage
and shape the tumor stroma in favor of cancer cell survival and
expansion (6, 10, 11).
Will this knowledge base in the field of inflammation, immu-
nity, and cancer lead to new, highly effective, and biologically
safe cancer immunotherapy modalities? We assert that the out-
come will depend upon the philosophy and the strategic goals
that will dominate the bench-to-bedside research. We propose
that research in this field should focus upon stimulating systemic
innate immune balance and adaptive immune resiliency, making
the mammalian host more powerful to resist its cancer challenger.
One possible approach utilizes gut microbiota or microbial anti-
gens to stimulate beneficial immune cells. On the other hand,
existing immunotherapy aims to selectively interrupt immune fac-
tors to better recognize and exterminate cancer cells (12–17), an
approach that may ultimately lead to host instability. To further
explain this point of view, we will refer to the recently discovered
paradoxical roles of regulatory T-cells (TREG) in cancer (10, 14).
TREG ARE CENTRAL IN PRESERVING SYSTEMIC IMMUNE
HOMEOSTASIS AND GOOD HEALTH
FOXP3+ CD4+ CD25+/high TREG are dominant cellular elements
of the professional suppressor arm of the immune system and are
important for orchestrating the control of peripheral immuno-
logical tolerance (18). The transcription factor FOXP3 is a funda-
mental regulator of TREG function in rodents and humans, and so
far the most reliable phenotypic indicator of their identity. Recent
studies on human TREG subpopulations, however, revealed that
low but discernible levels of FOXP3 expression could be detected
in non-suppressive TREG or even in activated effector T-cells. It is
probable that this finding reflects the inherent plasticity of TREG;
FOXP3+ cells co-expressing effector T-cell phenotypic markers or
cytokines may be in stages of a progressive, epigenetically regu-
lated, phenotypical, and functional shift process (14, 16, 19–22),
ultimately favorable for healthful recovery of the host after envi-
ronmental challenges. The role of TREG is central in preserving
immune system homeostasis for health and the balance of bene-
ficial inflammatory responses during infections while minimizing
collateral tissue damage. In cancer, however, roles of TREG are
traditionally considered to be negative (14–16, 23).
TREG GATHER NEAR TUMORS AND FAVOR CANCER SURVIVAL
A large body of data suggest that TREG gather near tumors and sup-
press the anti-tumor inflammatory response, thus favoring cancer
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cell survival. To this end, tumor-associated TREG are thought as
a major impediment of anti-tumor vaccines (13–16, 23). Clin-
ical and experimental data suggest that tumor-associated TREG
recognize both self and neoantigens expressed by tumor cells,
counteracting antigen-specific effector T-cell responses. Conse-
quently, immunotherapy strategies based on the vaccination with
tumor-associated antigens fail to evoke an effective response
against cancer cells due to the activation and expansion of tumor
antigen-specific TREG (14–16). This potential interplay of TREG
within tumors has been reviewed in detail elsewhere (12–16), and
has led to the proposal of several anti-TREG regimens for can-
cer immunotherapy. These regimens aim to deplete TREG, inhibit
their suppressive function, prevent their homing into tumor sites,
or block their differentiation/proliferation (12–16).
Several of these TREG-targeting modalities have already been
tested in the clinic, with mixed results (13, 16). Blocking TREG
function by depleting the cytotoxic T-lymphocyte-associated anti-
gen 4 (CTLA-4) appears promising (24), due to the depletion of
TREG from tumor tissues (25, 26). However, a similar regimen
could lead to an opposite effect with the accumulation of TREG and
CD8+ T-cells in tumors (27, 28). A phase III study of melanoma
patients using a gp100 peptide vaccine with interleukin (IL)-2
administration led to equally promising results with discovery of
TREG expansion in responding patients (29).
GUT MICROBIOTA INDUCE POTENT TREG WITH SYSTEMIC
ANTI-NEOPLASTIC PROPERTIES
As the results of these trials are anticipated, the literature reveals
contradictory evidence. Indeed, the studies associating high den-
sities of tumor-associated cells expressing TREG markers including
FOXP3 with a poor prognosis in several types of human cancers are
now challenged by similar studies on the very same types of cancer
showing the opposite outcome (30–34). The different CD8+:TREG
ratios and the presence of FOXP3+ cell subsets of undetermined
identity in the tumor microenvironment have been proposed as
probable explanations (16). Indeed, data from animal models
show under certain conditions of microbial priming that TREG not
only protect but also alter the tumor microenvironment to induce
remission of already established intestinal, mammary, and prostate
cancers (35–41). The hypothesis that the composition of the differ-
ent subsets of FOXP3+, which may include effector Foxp3+ cells, is
intriguing (16). Indeed, it was previously shown that IFN-γ levels
were increased during TREG-mediated tumor regression in mice
(37). Further, feeding of probiotic microbes to mice induces sys-
temic oxytocin secretion that shifts immunity toward IFN-γ and
CD25 for improved wound healing capacity and systemic good
health (42). A question subsequently arising is whether gut micro-
biota may be engineered to harness an anti-neoplastic FOXP3+
cell milieu (5, 10, 41).
GUT-CENTRIC HYPOTHESIS: PRIOR EXPOSURES TO
MICROBES EXPLAIN BENEFICIAL ROLES OF TREG
Stimulated by a gut-centric systemic homeostasis hypothesis, we
set out to explore and explain the paradoxical roles of TREG in
cancer using several different mouse models of cancer and adop-
tive cell transfer methodologies (10). We found that TREG may
suppress, promote, or have no effect in carcinogenesis depending
upon their timing and prior exposure to gut bacterial antigens
and presence of IL-10 (35–39, 41, 43, 44). Under some conditions,
adoptive transfer of TREG rapidly led to apoptosis of emerging
tumor cells (37, 45). Using as a model organism an opportunistic
pathogen, Helicobacter hepaticus, commonly residing in the lower
bowel of mice, we have shown in Rag2-deficient mice (otherwise
lacking lymphocytes) that gut microbiota modulate inflamma-
tory bowel disease and inflammation-associated colon cancer, a
cancer process inhibited by properly functioning IL-10-dependent
TREG (35, 36). Subsequently, by introducing H. hepaticus into the
large bowel flora of mice lacking the APC tumor suppressor gene
(ApcMin/+), we found that intestinal polypogenesis was greatly
enhanced by bacteria and subsequently suppressed by immune-
competent TREG. Furthermore, adenomas of infected ApcMin/+
mice progressed into adenocarcinoma, a transition atypical of
polyps of aged-matched uninfected controls (38, 41). Interestingly,
ApcMin/+ mice having H. hepaticus in their gut flora were prone to
develop cancer in tissues distant from intestine, such as prostate
and the mammary glands (40, 41, 43, 46, 47). H. hepaticus-induced
tumorigenic events were inhibited by supplementation with TREG
from immune-competent wild type donor mice.
A potent treatment to counteract these local and systemic H.
hepaticus-induced tumorigenic events was supplementation with
TREG in an IL-10-dependent manner (10, 36, 38–40, 44, 46, 48).
Purified TREG exhibited greatest anti-cancer potency when taken
from donor mice previously colonized with H. hepaticus. By con-
trast, TREG taken from donor mice without prior H. hepaticus
exposure were ineffective, and in some cases actually enhanced
tumorigenesis (10). Based on these results, we theorize that the
tumor microenvironment is subject to systemic inflammatory
events arising from environmental exposures in the gastrointesti-
nal tract (Figure 1). This microbe-inducible pro-inflammatory
condition contributes to tumor trophic signaling. Interestingly,
bacterial antigen triggered IL-10-dependent activities in the GI-
tract impart sustained protection from the aforementioned events,
resulting in immune cell recruitment, including TREG, which, by
being more potent in their anti-inflammatory roles, work locally
and systemically to suppress sepsis, myeloid precursor mobiliza-
tion, and inflammatory signaling important in extra-intestinal
cancer evolution (10, 43). These systemic events comprise the
tumor macroenvironment.
The roles of intestinal microflora in promoting cancer devel-
opment within the bowel have been well established (35, 49–52).
Linking gut microbial flora and local and systemic effects that pro-
mote (38) or suppress (45) tumors throughout the body, expands
this paradigm in a challenging manner. Recent findings show that
gut flora imbalances considerably undermine the response to both
immune (53, 54) and non-immune chemotherapeutic regimens,
such as cisplatin and oxaliplatin (53).
AWEAKENED TREG FEEDBACK LOOP UNIFIES AUTOIMMUNE
DISEASES AND CANCER
These gut microbe-centric findings in mice are consistent with
the “hygiene hypothesis,” according to which insufficient micro-
bial exposures earlier in life predispose to allergies, autoimmune
disorders, and uncontrollable inflammation-associated patholo-
gies later in life. We have shown that the basic principles of this
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FIGURE 1 | Gut bacteria–host crosstalk is continuous and reciprocal in
the cancer macroenvironment. Beneficial microbes trigger IL-10-mediated
GI-tract immune and neuronal networks that lower systemic inflammatory
tone and up-regulate hypothalamic–hypophyseal targets, including oxytocin,
constituting a gut–systemic immunity-endocrine-axis. In this way,
microbiota stimulate CD4+ lymphocytes including regulatory T cells (TREG)
that suppress, promote, or have no effect in carcinogenesis depending
upon their timing and prior exposure to gut bacterial antigens and presence
of interleukin (IL)-10. This places neoplastic development and growth into a
new broader context of the holobiont (comprised of the mammalian host
plus resident microbes) and the cancer macroenvironment, highlighting
microbes that may be engineered for sustained good health.
hypothesis may apply not only to auto-immunity, but also to
neoplastic disease as well, and that TREG play a central role in
this phenomenon (10, 41, 55). The ability of TREG to decrease
risk for cancer and counteract established tumors depends upon
microbe-triggered IL-10, which works to maintain immune sys-
tem homeostasis and reinforce a protective anti-inflammatory,
anti-neoplastic TREG phenotype (41). TREG display inherent phe-
notypic plasticity (10). Hygienic individuals with a weakened
IL-10 and TREG feedback loop are prone to a re-direction of
unstable resting peripheral TREG toward a T helper (Th)-17 pro-
inflammatory process. As a result “hygienic” subjects are at higher
risk to develop auto-immune diseases and cancer (10). It is tempt-
ing to postulate that this may explain why only a few people go on
to develop cancer, while nearly everyone bears dysplastic and early
neoplastic lesions throughout their body (56).
Depending on composition of gut microbiota, the immune
system of mice may acquire different subclinical characteristics,
even in the absence of overt inflammatory processes. The clinically
silent immune system status may determine the risk of develop-
ing sporadic cancer in epithelia throughout the body. Further,
we found that consuming beneficial probiotic bacteria led to the
expansion of a Foxp3+ cell population in the periphery (42, 45,
57) conferring protection to diet-related and genetic predisposi-
tion to mammary cancer (45). Targeted oral challenge with such
probiotic bacteria resulted in the activation of interrelated systemic
inflammatory and metabolic pathways, either through blood cir-
culation or via the vagus nerve (Figure 1). Consequently, there
was an upregulation of systemic hormone levels, such as oxytocin,
testosterone, and thyroxin. Oxytocin serves to sustain immune and
integumentary homeostasis, biasing the immune system toward
IL-10 and IFN-γ, without anergy, subsequently minimizing the
deleterious systemic effects of IL-17 (57). This altered immune sys-
tem and metabolic profile of mice imparted healthful phenotypes
including shiny fur and youthful hair follicle cycling, accelerated
skin wound healing capacity, and resistance to diet-induced obe-
sity and senility (42, 47, 57, 58). Through tightly regulated immune
activities, competent TREG permit brief beneficial host inflamma-
tory responses to eliminate invading pathogens, and later inhibit
chronic deleterious inflammatory tissue damage (43). The results
of our wound healing assays further suggest that the probiotic
microbe-induced enhancement of the TREG-dominated arm of
the immune system did not compromise the ability of mice to
respond to invading pathogens (42).
BENEFICIAL SYSTEMIC EFFECTS OF GUT MICROBES ARE
TRANSPLANTABLE VIA FOXP3+ TREG INTO NAÏVE HOSTS
Adoptive cell transfer models offer mechanistic insight as these
beneficial effects were isolated to bacteria-primed TREG (42, 47,
57–59). In fact, healthful phenotypes were entirely reproducible
in naive recipient mice by the adoptive transfer of highly purified
TREG derived from probiotic-fed cell donors (42, 57, 59). These
results suggest gut microbe-induced crosstalk with the host in
a continuous and reciprocal manner. The fate of preneoplastic
and neoplastic lesions arising in epithelia throughout the body
depends upon this macroenvironment at the whole organism
level. Consequently, the tumor macroenvironment is defined as
the “holobiont,” i.e., the mammalian organism plus the micro-
bial symbionts it bears. The TREG population is a central player
of the tumor macroenvironment connecting gut bacteria with
reproductive fitness, youthful phenotypes, and anti-neoplastic
properties.
MICROBIAL ENGINEERING OFFERS NEW STRATEGIES FOR
PUBLIC HEALTH
Taken together, microbial engineering strategies using food-grade
bacteria highlight alternative directions in cancer immunother-
apy. Modulating beneficial TREG via diet is a biologically safe and
efficient approach, originating from genetic programs that have
been shaped during the millions of years of co-evolution of mam-
mals with their gut bacteria symbionts. These attributes remain
largely inactive in individuals with a modern lifestyle, Western-
ized dietary habits, and stringent hygiene practices. Awakening
these latent TREG-mediated capabilities may provide an alterna-
tive avenue to reduce cancer risk at a population level for public
health. The perspectives presented here should be considered as
an alternative paradigm – not only for fighting cancer – but also
for promoting overall good health and longevity.
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